share_log

Needham Maintains Buy on Cara Therapeutics, Lowers Price Target to $6

Benzinga ·  Dec 18, 2023 23:29

Needham analyst Joseph Stringer maintains Cara Therapeutics (NASDAQ:CARA) with a Buy and lowers the price target from $22 to $6.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment